SHOP APOTHEKE EUROPE completes capital increase against contribution in kind and acquires Europa Apotheek Venlo.

NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.
 

SHOP APOTHEKE EUROPE completes capital increase against contribution in kind and acquires Europa Apotheek Venlo.
 

Venlo/Cologne, 08 November 2017. SHOP APOTHEKE EUROPE N. V. has successfully completed the acquisition of the mail-order pharmacy Europa Apotheek Venlo by acquiring the entire issued and outstanding share capital of its parent company EHS Europe Health Services B. V. ("EHS"). Such acquisition was structured by way of issuance of a total of 2,950,578 new shares with a nominal value of EUR 0.02 each in SHOP APOTHEKE EUROPE N.V. (the "New Shares") to the shareholders of EHS under the obligation to pay up the New Shares by way of contribution of their shares in EHS. The New Shares are in bearer form, are entitled to dividends as from 1 January 2017 and are expected to be listed on the regulated market segment (regulierter Markt) of the Frankfurt Stock Exchange as of 10 November 2017 under the existing stock exchange symbol "SAE", the ISIN NL0012044747 and the securities identification number (WKN) A2AR94. All the New Shares are subject to a lock-up period of 180 days following the first day of trading of the New Shares on the Frankfurt Stock Exchange. The listing prospectus was approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) on 7 November 2017 and notified to the German Federal Financial Supervisory Authority (BaFin) on the same day.

As a result of the completion of the transaction, the total number of outstanding shares of SHOP APOTHEKE EUROPE N.V. has increased from 9,069,878 to 12,020,456 shares.

 

ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is Continental Europe's leading online OTC pharmacy with a portfolio that focuses on OTC medication and pharmacy-related beauty and care products (BPC). With the acquisition of Europa Apotheek, SHOP APOTHEKE EUROPE significantly enhanced its European market leadership with an expanded product range for the whole family. The combination will create the fastest growing integrated online pharmacy with pro forma sales of around EUR 318 m in 2016.

SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and The Netherlands. In Germany, the TÜV-certified shop-apotheke.com is the market leader in terms of traffic. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to more than 2.4 m active customers quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services.

SHOP APOTHEKE EUROPE generated sales of about EUR 191 m in the first nine months of 2017 and growth of +53% compared to the same period last year. Headquartered in Venlo (the Netherlands), SHOP APOTHEKE EUROPE also has offices in Cologne, Düsseldorf and Tongeren, Belgium. The online pharmacy has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016.

 

MEDIA CONTACTS.

Trade and public media:
Sven Schirmer
Mobil: +49 152 28 50 63 61
E-Mail: presse@shop-apotheke.com

Financial media:
Thomas Schnorrenberg
Mobil: +49 151 46 53 13 17
E-Mail: presse@shop-apotheke.com

Investor Relations:
Dr. Ulrich Wandel
Telefone: +31 77 850 6117
E-Mail: ulrich.wandel@shop-apotheke.com

 

DISCLAIMER.
This publication is an advertisement.
This communication constitutes neither an offer to sell nor a solicitation to buy securities of Shop Apotheke Europe N.V. in any jurisdiction. This is not a securities prospectus. No public offering of any securities of Shop Apotheke Europe N.V. is being made.

Statements contained herein may constitute "forward-looking statements." Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "plan", "expect", "anticipate", "estimate," "believe", "intend", "project", "goal" or "target" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Group's or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. You should not place undue reliance on forward-looking statements and the Group does not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise.